Overview & Series Context
This lesson bridges Lesson 1 (pathogenesis, Braak staging, prodromal overview) and Lesson 2 (genetics) into the clinical domain: how do we diagnose PD with precision in 2026? The answer has changed dramatically — from pattern recognition to a biomarker-integrated framework anchored by α-synuclein biology.
- 從病理→基因 (L1+L2) 到 臨床診斷 (L3)
- 核心診斷工具：MDS-UPDRS、2015 MDS 診斷標準（深度應用）
- 影像：DAT-SPECT、MIBG、先進 MRI
- 生物標記：α-突觸核蛋白 SAA（CSF、皮膚、腸道）
- 前驅期 PD：body-first vs brain-first、SAA 整合生物定義
PRISMA — Literature Search Flow
(PubMed + OE + local Drive + supplementary)
(IF≥3, relevance, study design)
(45 online + 3 local Drive; all PMIDs verified)
Lesson 2 已覆蓋（本課完全不重複）： 所有遺傳學內容。
Motor Cardinal Features
Phenomenology & Mechanism1.1 Bradykinesia — The Essential Core Feature
By 2015 MDS criteria, bradykinesia is defined as slowness of movement with progressive reduction in speed AND amplitude during repetitive motion — this amplitude decrement is the clinically operationalized hallmark, not mere slowness alone.[1] The decrement must be documented in finger tapping, hand movements, heel-ground tapping, or leg agility.
Mechanistic basis: reduced dopaminergic output from SNpc → decreased D1-mediated direct pathway activation + increased indirect pathway inhibition → net over-inhibition of thalamo-cortical motor circuits → impaired movement initiation and amplitude scaling.[40]
Hypokinesia = reduced amplitude; Akinesia = absence of spontaneous movement; Bradykinesia = slowed movement — all three exist on a continuum. Facial bradykinesia (hypomimia, reduced blink), vocal bradykinesia (hypophonia, monotone), and ocular bradykinesia (slow saccades) extend beyond limbs. Key teaching point: fatigue alone without amplitude decrement does NOT qualify as bradykinesia by MDS criteria.[3]
1.2 Rest Tremor — Subtypes and Clinical Distinctions
Classic 4–6 Hz resting tremor, typically asymmetric, "pill-rolling" quality. Suppressible with voluntary movement; re-emerges after maintained posture (re-emergent tremor). Present in ~70–75% of PD at presentation; ~5–10% never develop tremor (PIGD phenotype).[3][41][48]
| Tremor Type | Frequency | Context | DAT | Clinical Meaning |
|---|---|---|---|---|
| Classic rest tremor | 4–6 Hz | At rest | Abnormal | PD (most specific motor sign) |
| Re-emergent postural tremor | 4–6 Hz | After held posture 10–15 s | Abnormal | PD — same oscillator as rest tremor |
| Jaw / chin tremor | 4–6 Hz | At rest | Abnormal | PD-specific; NOT seen in ET |
| Head tremor | Variable | Action / rest | Normal | Atypical for PD → favour ET or dystonic tremor |
Rest tremor is a supportive criterion in MDS 2015 — its presence increases diagnostic confidence; its absence does NOT exclude PD.[1]
1.3 Rigidity
Increased resistance to passive movement throughout range of motion, velocity-independent (lead-pipe). Superimposed tremor produces cogwheel phenomenon — cogwheeling is NOT a separate sign.
Froment's maneuver: patient performs voluntary repetitive movement with contralateral limb → rigidity increases in examined limb → enhances detection of subtle rigidity (most sensitive clinical maneuver for early PD rigidity).[3]
Distribution: limb rigidity > axial rigidity in PD — the reverse (axial > limb, "nuchal rigidity") suggests PSP. Paratonia (gegenhalten; velocity-dependent) implies cortical pathology (CBS, NPH), not PD.[11]
1.4 Postural Instability & Gait Disorder (PIGD)
Emerges later; early appearance (<3 years) is a red flag for atypical parkinsonism.[1] Pull test: ≥3 corrective steps or fall = PIGD (MDS-UPDRS Part III item 30).
| Gait Feature | Description | Clinical Note |
|---|---|---|
| Shuffling gait | Reduced stride length, foot clearance | Classic PD gait; early finding |
| Reduced arm swing | Asymmetric early; symmetric later | Bilateral symmetric = atypical |
| Festination | Accelerating, forward-leaning small steps | Increased fall risk |
| Freezing of gait (FoG) | Episodic; worse with dual-task, turns, doorways | Not early in typical PD |
| Camptocormia | Marked anterior trunk flexion >45° | Advanced PD or MSA; not CBS |
- 運動遲緩（bradykinesia）是診斷 parkinsonism 的必要條件；「振幅遞減」才是關鍵，非單純「緩慢」
- 再現性姿勢性震顫（re-emergent tremor）與靜止性震顫同屬 PD 振盪迴路，不應誤判為 ET
- Froment's 手法可提升早期 PD 僵直偵測靈敏度
- 起立不穩在 PD 多為晚期表現；若發病 3 年內出現應強烈懷疑非典型帕金森症
Non-Motor Symptoms (NMS)
Classification & Diagnostic SignificanceNMS precede motor onset by years-to-decades and contribute more to disability and quality of life than motor features in advanced disease.[4] Bloem, Okun & Klein 2021 Lancet established the conceptual reframe: PD is a multisystem disease with NMS at its core, not a motor disorder with incidental NMS.[4]
2.1 Domain Classification
| Domain | Key Symptoms | Prevalence in PD | GRADE |
|---|---|---|---|
| Gastrointestinal | Constipation (earliest), drooling, dysphagia, nausea | 70–80% | ⊕⊕⊕⊕ High |
| Autonomic | Orthostatic hypotension, urinary urgency/retention, sexual dysfunction, sudomotor | 50–75% | ⊕⊕⊕⊕ High |
| Sleep | RBD (PSG-proven 40–60%), PLMD, EDS, insomnia | 60–90% | ⊕⊕⊕⊕ High |
| Neuropsychiatric | Depression ~40%, anxiety ~40%, apathy 40%, psychosis ~25%, ICD | 40–70% | ⊕⊕⊕⊕ High |
| Cognitive | MCI-PD → PDD; 75–80% cumulative lifetime risk | 27% at dx; 80% over 20 yr | ⊕⊕⊕⊕ High |
| Sensory | Hyposmia ≥85%, pain 40–60%, paresthesia | >85% for anosmia | ⊕⊕⊕⊕ High |
| Fatigue | Independent of motor disability; 50–60% | 50–60% | ⊕⊕⊕⊝ Moderate |
2.2 Key NMS Statistics
Depression: meta-analysis of 129 studies (Cong et al. 2022) — pooled prevalence ~35%; independent predictor of QoL and caregiver burden; often underdiagnosed in PD.[36]
Cognitive impairment: Aarsland et al. 2021 Nat Rev Dis Primers — MCI-PD in ~27% at diagnosis; 75–80% cumulative lifetime risk of PDD; mediated by α-syn spread, cholinergic degeneration, and Alzheimer co-pathology.[35]
PD psychosis: Pagonabarraga et al. 2024 Nat Rev Neurol — spectrum from minor hallucinations (illusions, presence/passage) → formed visual hallucinations → delusions; strong predictor of nursing home placement; dopaminergic treatment is a risk factor but not the sole cause.[37]
2.3 NMS as Diagnostic Signals
| NMS | Prevalence in PD | Diagnostic Role | Note |
|---|---|---|---|
| Hyposmia | >85% | Supportive criterion (MDS 2015) | Absent in ET, DIP → high specificity for synucleinopathy |
| iRBD | 40–60% | Strongest prodromal marker | >80% α-syn SAA+; 85–90% phenoconversion over 14 yr[19][29] |
| Constipation | 60–70% | Prodromal marker (10–20 yr pre-motor) | Especially gut-first PD subtype |
| Severe orthostatic hypotension (≥30/15 mmHg, <5 yr) | Mild common; severe 15% | Red flag for MSA-P | Mild autonomic dysfunction ≠ red flag in PD |
| Cardiac MIBG denervation | ~70% | Supportive criterion (MDS 2015) | H/M ratio early <1.6; distinguishes PD/DLB from MSA |
- NMS 多數早於動作症狀出現數年；嗅覺喪失與 iRBD 是最重要的前驅標記
- 抑鬱症（~35%）與認知障礙（PDD 終身風險 ~80%）對 QoL 影響大於動作症狀
- 嚴重自律神經失調（發病 5 年內）為警示徵象，需排除 MSA
- NMS 問卷（NMSQuest、MDS-NMSQuest）可系統評估常被忽略的 NMS
MDS-UPDRS
Structure, Scoring & Clinical UtilityThe MDS-Unified Parkinson's Disease Rating Scale (2008 revision, Goetz et al.) is the gold-standard severity measurement tool across all PD research and clinical trials.[5] It replaces the original UPDRS with better sensitivity and validated range across all disease stages.[5]
3.1 Four-Part Structure
| Part | Title | Items | Informant | Key Content |
|---|---|---|---|---|
| I | Non-motor experiences of daily living | 13 | Patient + caregiver | Cognition, hallucinations, depression, anxiety, apathy, urinary, pain, fatigue |
| II | Motor experiences of daily living | 13 | Patient self-report | Speech, drooling, swallowing, tremor, gait, freezing, dressing |
| III | Motor examination | 33 (18 items) | Clinician | Bradykinesia (10), rigidity (5 sites), tremor (6), gait/posture (6), pull test |
| IV | Motor complications | 6 | Clinician | Dyskinesia (time, impact, pain) + motor fluctuations (OFF duration, impact, complexity) |
3.2 Key Clinical Thresholds
| Metric | Value | Source |
|---|---|---|
| MCID for Part III Motor | 2.5 points | Horváth et al. 2015 [9] |
| Mild PD (Part III) | <32 | Martinez-Martin 2015 |
| Moderate PD (Part III) | 32–58 | |
| Severe PD (Part III) | >58 | |
| Typical annual progression | ~2–4 points/year (Part III) | PPMI observational data |
3.3 Levodopa Challenge Protocol
Document MDS-UPDRS Part III in OFF state (≥12 h medication withdrawal or ≥1 h post-last-dose), then administer adequate levodopa dose (≥600 mg/day levodopa equivalent in moderate disease) and reassess at 60–90 min peak dose. ≥33% improvement = definitive positive levodopa response — required for "Clinically Established PD" if only 1 of 4 supportive criteria is otherwise met.[1][2]
- 4 部分共 65 題；Part III（動作檢查）是研究主要終點，MCID = 2.5 分
- Part I 系統性捕捉 NMS，臨床常規問診易遺漏
- Levodopa challenge：OFF → peak dose（60–90 min） → Part III 改善 ≥33% 為陽性
- 幾乎所有 PD 臨床試驗以 MDS-UPDRS Part III 為主要療效指標
2015 MDS Clinical Diagnostic Criteria
Deep Application — Beyond the Overview4.1 Two Certainty Levels — Sensitivity/Specificity Data
The 2015 MDS criteria introduced two diagnostic certainty levels, each with distinct sensitivity–specificity trade-offs validated in a clinicopathological cohort of 129 autopsy-confirmed PD cases (Postuma et al. 2018).[2]
| Level | Sensitivity | Specificity | Requirement | Clinical Use |
|---|---|---|---|---|
| Clinically Probable PD | ~96% | ~95% | No exclusion + ≤2 red flags, each counterbalanced by ≥1 supportive criterion | Routine clinical diagnosis; trial enrollment |
| Clinically Established PD | ~59–73% | ~98.5–99% | No exclusion + no red flags + all 4 supportive criteria | Medicolegal; research requiring near-certainty |
Take-home: Probable PD is the workhorse diagnosis — high sensitivity and high specificity simultaneously. Established PD sacrifices sensitivity for near-perfect specificity (useful for autopsy correlation studies and high-stakes decisions).[2]
4.2 Absolute Exclusion Criteria — Practical Application
Any single criterion definitively rules out PD (not "argues against" — it excludes): [1]
| Absolute Exclusion Criterion | Clinical Implication |
|---|---|
| Cerebellar signs (ataxia, cerebellar dysarthria, nystagmus) | → Consider MSA-C, SCA |
| Downward vertical supranuclear gaze palsy | → PSP (upward gaze palsy alone is NOT exclusionary) |
| bvFTD or PPA diagnosis within first 5 years | → CBS/FTD-Parkinsonism |
| Parkinsonism restricted to lower limbs >3 years | → Vascular parkinsonism |
| Dopamine receptor blocker / depleter in dose/time relationship | → Drug-induced parkinsonism (rule out PD unmasked) |
| No levodopa response despite adequate dose at moderate severity | → Atypical; requires ≥600 mg/day levodopa equivalent (moderate stage) |
| Cortical sensory loss / clear ideomotor limb apraxia / progressive aphasia | → CBS |
| Normal functional neuroimaging of presynaptic dopaminergic system | → ET, DIP, functional tremor |
| Alternative condition fully explaining parkinsonism | → Document the alternative diagnosis |
4.3 Red Flags — Clinical Application
Each red flag must be neutralized by an additional supportive criterion (beyond baseline requirements for Probable PD): [1]
| Red Flag | Time Frame | Alternative Diagnosis to Consider |
|---|---|---|
| Rapid progression to wheelchair | <5 years | PSP, MSA |
| Complete absence of disease progression | ≥5 years | Drug-induced, functional |
| Early severe dysphonia/dysarthria | <5 years | MSA (stridor), PSP (hypophonia) |
| Inspiratory respiratory dysfunction / stridor | Any | MSA (near-pathognomonic) |
| Severe autonomic failure | <5 years | MSA-P (OH ≥30/15 mmHg + urinary retention/incontinence) |
| Recurrent falls from impaired balance | <3 years | PSP |
| Disproportionate anterocollis or contractures | <10 years | MSA (not camptocormia); rare in PD |
| Absence of common NMS despite ≥5 years | ≥5 years | Consider re-evaluation; atypical |
| Otherwise unexplained pyramidal tract signs | Any | MSA-P, CBS, vascular |
| Bilateral symmetric parkinsonism | From onset | DIP, vascular, PSP |
4.4 Supportive Criteria
| Supportive Criterion | Clinical Application |
|---|---|
| Clear dramatic beneficial response to dopaminergic therapy | Documented Part III improvement ≥33% or clinical equivalence |
| Presence of levodopa-induced dyskinesia | Even subtle choreiform movements; counts as supportive |
| Rest tremor of a limb on clinical exam | Must be documented on examination, not just history |
| Olfactory loss OR cardiac sympathetic denervation on MIBG | Olfactory: UPSIT/sniff test; MIBG H/M <1.6 early phase |
4.5 Autopsy Validation — 2025 Update
Fox et al. 2025 npj PD PMID 41390531 — retrospective autopsy-confirmed PD study:[8]
- Supranuclear gaze palsy, rapid gait progression to wheelchair, and bilateral onset symptoms were each present in >5% of pathologically confirmed PD cases
- Implication: some red flags may be overly restrictive, particularly for atypical disease variants
- Clinical accuracy in expert centers: ~80–90%; autopsy remains gold standard
- Probable PD：敏感度 ~96%、特異度 ~95%（日常臨床診斷首選層次）
- Established PD：特異度 ~98.5%，但犧牲靈敏度（~59%）—— 適用高確定性需求場景
- 絕對排除標準任一條即排除 PD；「向下」垂直注視麻痺（非向上）才是排除標準
- 「無 levodopa 反應」需充足劑量（≥600 mg/day）且中等嚴重度方成立
- Fox 2025 屍解資料：部分紅旗（如雙側起病）仍見於 >5% 確診 PD — 標準仍需前瞻性再驗證
Differential Diagnosis
Recognition Patterns — ET, DIP, PSP, MSA, CBS5.1 PD vs Essential Tremor (ET)
Most common tremor misdiagnosis (~20–30% of tremor patients initially misclassified).[6] The key discriminating feature at the bedside is the re-emergent tremor test: ask patient to hold arms outstretched — ET tremor appears immediately; PD re-emergent tremor appears after a latency of ~10–15 seconds.[3][6]
| Feature | PD | Essential Tremor |
|---|---|---|
| Tremor character | Rest tremor ± re-emergent postural | Action/kinetic/postural; no rest (usually) |
| Frequency | 4–6 Hz | 5–10 Hz |
| Distribution | Asymmetric; pill-rolling; jaw/chin | Bilateral; head/voice common |
| Bradykinesia | Required for parkinsonism | Absent |
| Alcohol response | No | Yes (50–70%) |
| Family history | Less common (except LRRK2) | Common (~50% AD) |
| DAT-SPECT | Abnormal | Normal |
| α-syn SAA | Positive (~91%) | Negative |
5.2 PD vs Drug-Induced Parkinsonism (DIP)
DIP accounts for 7–12% of all parkinsonism.[7] The temporal relationship to drug initiation is the key clue. Common causative agents: antipsychotics (dopamine D2 blockers), antiemetics (metoclopramide, domperidone), calcium channel blockers (flunarizine, cinnarizine).[7]
| Feature | DIP | PD |
|---|---|---|
| Temporal onset | Weeks–months after drug initiation | Insidious, years |
| Symmetry | Often bilateral/symmetric at onset | Asymmetric |
| DAT-SPECT | Normal (presynaptic intact) | Abnormal |
| Course after drug cessation | Resolves weeks–months | Progressive |
| Important caveat | DIP can unmask underlying PD (15–20% of DIP have abnormal DAT-SPECT) — may not resolve after drug withdrawal | |
5.3 Recognition Red Flags for Atypical Parkinsonism
Recognition only — no detailed management in this series (pure PD curriculum)
| Feature | PSP | MSA | CBS |
|---|---|---|---|
| Most distinctive sign | Vertical supranuclear gaze palsy (downward) | Early severe autonomic failure; stridor; cerebellar signs (MSA-C) | Alien limb; ideomotor apraxia; cortical sensory loss |
| Falls | Early (<3 yr), backward | Early (<3 yr), variable | Variable |
| Levodopa response | Poor | Variable (initial → wanes) | Poor |
| Symmetry | Symmetric / axial-predominant | Symmetric | Asymmetric |
| α-syn SAA | Negative (tauopathy) | Negative (different α-syn strain) [22] | Negative (tauopathy) |
| MRI hallmarks | "Hummingbird" sign; midbrain atrophy | "Hot-cross bun" (MSA-C); putaminal rim; atrophy | Parietal/frontal atrophy; asymmetric cortical thinning |
α-Syn SAA discrimination: CSF SAA sensitivity for PD vs PSP ~92%, specificity ~84–86% (Anastassiadis et al. 2024 Neurology).[23] For MSA, a specific MSA α-syn SAA shows sensitivity ~50%, specificity ~95% — still under validation.[22]
- ET vs PD：「再現性姿勢性震顫」出現潛伏期 10–15 s 是床邊鑑別關鍵；DAT-SPECT 是金標準
- DIP vs PD：台灣常見元凶：metoclopramide、domperidone（常被忽略）；DAT 正常 → DIP
- MSA 紅旗：5 年內嚴重自律神經失調 + 喘鳴 + 小腦症狀
- CBS 紅旗：不對稱肢體失用 + alien limb + 皮質感覺喪失
- α-syn SAA (CSF) 可區分 PD 與 PSP/CBS（陰性），但 MSA 特異型 SAA 尚在驗證中
Neuroimaging
DAT-SPECT, MIBG & Advanced MRI6.1 DAT-SPECT (¹²³I-FP-CIT / DaTSCAN)
Images presynaptic dopamine transporter (DAT) density in the striatum. Reflects nigrostriatal dopaminergic integrity. Normal DAT-SPECT = absolute exclusion criterion for PD.[1][12]
| Parameter | Value | Source |
|---|---|---|
| Sensitivity (neurodegenerative parkinsonism vs controls) | ~77–80% | EANM guideline [12] |
| Specificity vs ET / DIP / psychogenic | ~90–95% | EANM guideline [12] |
| Can distinguish PD from PSP/MSA/CBS? | No — all show reduced DAT binding | [39] |
| Pattern in PD | Asymmetric putaminal > caudate reduction ("comma/period" sign) |
Clinical indications (EANM/SNMMI 2020):[12]
- Tremor-dominant presentation: clinically uncertain rest vs action tremor
- Suspected DIP: drug washout impractical or atypical features persist
- Equivocal levodopa response: confirm presynaptic system integrity
- Research/trial enrollment verification
6.2 Cardiac ¹²³I-MIBG Scintigraphy
Images cardiac postganglionic sympathetic innervation — lost early in PD (Braak stages 1–2). Included as a supportive criterion in MDS 2015 criteria.[1]
| Parameter | Value | Source |
|---|---|---|
| Sensitivity for early PD | 68.5% | Kawazoe et al. 2019 [13] |
| Specificity for early PD | 95.2% | Kawazoe et al. 2019 [13] |
| H/M ratio threshold | Early phase H/M <1.6 → suggests PD/DLB | |
| Key discriminator | PD/DLB = denervated; MSA = preserved cardiac innervation | |
| Limitations | Lower sensitivity than DAT-SPECT; diabetes/cardiac disease affect results; LRRK2-PD often normal | Jagusch et al. 2026 [47] |
Jagusch et al. 2026 (Mov Disord Clin Pract) identify key practical limitations: (1) cardiac comorbidities — diabetes mellitus, heart failure, prior myocardial infarction — independently reduce ¹²³I-MIBG uptake and generate false-positive denervation patterns; (2) LRRK2-PD frequently shows preserved cardiac MIBG (reflecting Lewy body-sparse pathology, paralleling its 67.5% CSF SAA sensitivity); (3) DLB produces an identical denervation pattern to PD — MIBG cannot differentiate PD from DLB; (4) limited scanner availability and cost restrict routine use. Practical recommendation: reserve MIBG for cases where DAT-SPECT is indeterminate or when PD vs MSA differentiation is the primary question.[47]
6.3 Advanced MRI — Emerging (Not Yet Routine)
Conventional MRI is typically normal in PD — useful to exclude structural causes (vascular parkinsonism, NPH, mass lesion).[10]
AID-P Trial — Vaillancourt et al. 2025 JAMA Neurol:[32]
Automated diffusion-weighted MRI + machine learning: AUC 0.98 for PD vs PSP/MSA/CBS. Outperforms clinical assessment alone in atypical cases. Not yet a clinical standard.
Haller et al. 2025 Radiology (MRI biomarkers review):[33]
| MRI Technique | Finding in PD | Status |
|---|---|---|
| Neuromelanin-sensitive MRI (NM-MRI) | Reduced SN signal | Research; not routine |
| R2* mapping (iron) | Increased iron deposition in SN | Research; high PD sensitivity |
| Free-water fraction (posterior putamen) | Elevated in MSA vs PD → differential | Research; promising for atypical DDx |
| Conventional structural MRI | Normal in PD | Standard — useful to exclude mimics |
Martinez-Valbuena et al. 2026 Nat Med: multimodal biomarker strategy (SAA + imaging + fluid) achieves near-autopsy diagnostic precision for atypical parkinsonism.[34]
- DAT-SPECT：區分退化性（PD/PSP/MSA/CBS）vs 非退化性（ET、DIP）—— 特異度 ~90–95%；正常 DAT = PD 絕對排除標準
- DAT-SPECT 無法區分 PD 與 PSP/MSA/CBS（三者皆有 DAT 降低）
- MIBG 心臟閃爍掃描：PD/DLB 去神經化；MSA 保留 → 是 MDS 支持標準之一；早期 PD 敏感度 68.5%，特異度 95.2%
- 先進 MRI（NM-MRI、R2*、free-water fraction）：研究工具，尚未進入臨床常規
α-Synuclein Seed Amplification Assay (SAA)
The Transformative Diagnostic Biomarker — CSF, Skin, GutSAA detects misfolded α-synuclein "seeds" in biological fluids/tissues by inducing recombinant α-syn monomer to aggregate in vitro — a fluorescent signal indicates seed-competent pathological α-syn. This enables detection of pathology before imaging or clinical manifestation.[20]
7.1 Two Assay Platforms
| Platform | Mechanism | Primary Use |
|---|---|---|
| RT-QuIC (Real-Time Quaking-Induced Conversion) | Oscillating/thermostatic agitation of α-syn monomer with seed sample | CSF, skin (research) |
| PMCA (Protein Misfolding Cyclic Amplification) | Sonication-based cyclic amplification | Skin (more sensitive than RT-QuIC for skin) |
7.2 CSF α-Synuclein SAA — PPMI Landmark Study
Siderowf et al. 2023 Lancet Neurol PMID 37059509 — PPMI cohort (n=1,123):[14]
| Subgroup | Sensitivity | Specificity |
|---|---|---|
| PD overall | 87.7% | 94.9% vs healthy controls |
| Sporadic (typical) PD | 91.4% | |
| GBA1-PD | 95.8% | |
| LRRK2-PD | 67.5% ← lower (may lack Lewy bodies) | |
| Prodromal (iRBD, hyposmic) | 85.3% | 94.9% |
Biological staging: Orru et al. 2025 Lancet Neurol — SAA kinetic parameters (lag phase, fluorescence amplitude) predict motor progression speed and disease severity — potential for prognostication beyond diagnosis.[21]
Type discrimination: CSF SAA differentiates Lewy-type (PD/DLB) from MSA — high-intensity "type 1" vs low-intensity "type 2" reaction patterns — specificity ~97% for PD over MSA in selected studies.[22]
7.3 Skin Biopsy α-Synuclein
SYNABS multicenter study (Gibbons et al. 2024 JAMA PMID 38506839):[15]
N=428 (PD n=217, DLB n=94, MSA n=92, controls n=25) — 3-mm punch biopsies from abdominal + thigh + distal leg.
| Diagnosis | Sensitivity (pSer129 α-syn IF) | Specificity vs Controls |
|---|---|---|
| PD | 92.7% | 97–100% |
| DLB | 87.9% | 97% |
| MSA | 97.3% | (different signature pattern) |
Key: both PD and MSA show positive skin staining but signature patterns differ — neuronal autonomic fiber distribution (PD) vs different cellular distribution (MSA) → can discriminate with pattern analysis.[16]
Iranzo et al. 2023 Neurology (iRBD): skin RT-QuIC 72.7% + CSF RT-QuIC 90% — combined sensitivity 96% in prodromal iRBD population.[19]
7.4 Gastrointestinal Biopsy — Limited Clinical Utility
Zheng et al. 2023 Eur J Neurol SR/MA (25 studies): gut SAA sensitivity 44% (range 20–75%), specificity 92%.[18] Lower sensitivity limits standalone clinical utility; heterogeneous biopsy sites (sigmoid, rectum, appendix) complicate standardization.
Relevance: in the gut-first PD model, α-syn pathology initiates in the ENS → gut biopsy theoretically most promising early in this subtype, but clinical sensitivity remains low.[28]
7.5 Comparative Summary
| Source | Sensitivity (PD) | Specificity | Invasiveness | Availability | GRADE |
|---|---|---|---|---|---|
| CSF (RT-QuIC) | 87–91% | ~95% | Moderate (LP) | Research/specialist | ⊕⊕⊕⊕ High |
| Skin pSer129 IF | ~93% | 97–100% | Low (punch biopsy) | Specialized lab | ⊕⊕⊕⊕ High |
| Skin SAA (RT-QuIC/PMCA) | 80–96% | 90–100% | Low | Research only | ⊕⊕⊕⊝ Moderate |
| Gut (SAA/IHC) | ~44% | ~92% | Moderate–High | Research only | ⊕⊕⊝⊝ Low |
| Serum EV α-syn | ~80% (early data) | ~85% | Very low (blood draw) | Research only | ⊕⊕⊝⊝ Low |
- CSF α-syn SAA（PPMI 資料）：典型 PD 敏感度 91.4%、特異度 94.9%；前驅期 iRBD 85.3%
- LRRK2-PD 敏感度較低（67.5%）—— 可能缺乏路易體，SAA 依賴病理型態
- 皮膚活體穿刺（SYNABS 研究）：PD 敏感度 92.7%、特異度 97% —— 侵入性低、潛力最佳
- 腸道活體敏感度僅 44%，臨床獨立應用價值有限
- CSF SAA 型態（Type 1 vs 2）可區分 PD/DLB 與 MSA —— 未來臨床轉化關鍵
Prodromal PD & Biological Staging
Beyond the 2019 MDS Criteria — Body-First, SAA Integration, SynBioS8.1 Updated MDS Prodromal Criteria (2019)
Heinzel et al. 2019 Mov Disord updated the Bayesian probability algorithm for prodromal PD: [26]
- Framework: Bayesian probability integrating age + risk markers + prodromal markers
- Threshold for "probable prodromal PD": ≥80% probability
| Prodromal Marker | Likelihood Ratio (LR+) | Note |
|---|---|---|
| PSG-confirmed iRBD | ~130 | Strongest single predictor; >80% α-syn SAA+ |
| Abnormal DAT-SPECT | ~22 | Presynaptic dopamine loss in asymptomatic period |
| Hyposmia (UPSIT <15th percentile) | ~4.0 | Present >85% of PD; absent in ET/DIP |
| SN hyperechogenicity (TCS) | ~2.4 | Operator-dependent; not available everywhere |
| Constipation, depression, EDS | 2–3 each | Nonspecific; additive value in combination |
8.2 Body-First vs Brain-First PD Subtypes
Berg et al. 2021 Nat Rev Neurol and Borghammer & Van Den Berge 2019 proposed the body-first/brain-first hypothesis based on α-syn propagation patterns:[27][28]
| Subtype | Origin | Early Markers | Motor Phenotype | Proportion |
|---|---|---|---|---|
| Body-first (gut-first) | ENS → vagus → brain | Constipation, urinary dysfunction, iRBD, autonomic failure (often years before motor) | More NMS-dominant; tremor-predominant motor at dx | ~50% |
| Brain-first (amygdala-first) | Brain → peripheral spread | Hyposmia, cognitive change; minimal autonomic prodrome | Motor-onset predominant; less early autonomic | ~50% |
Liu et al. 2026 Brain PMID 41105632: distinct cutaneous α-syn signatures between body-first vs brain-first PD — body-first shows denser peripheral skin fiber involvement → potential subtype classification via skin biopsy in the future.[44]
8.3 iRBD Phenoconversion — Natural History Data
Joza et al. 2023 Brain PMID 36881989 (multicenter iRBD natural history, n=1,232):[29]
- Median phenoconversion time: ~7.5 years from iRBD diagnosis
- Annual conversion rate: ~6–8%
- 14-year cumulative conversion to synucleinopathy: ~85–90%
- Fastest converters: those with olfactory loss + abnormal DAT-SPECT + α-syn SAA+
Coughlin et al. 2025 Neurology: α-syn SAA kinetic parameters in prodromal PD (iRBD) predict phenoconversion speed — shorter lag phase → faster motor onset → stratification tool for neuroprotection trials.[30]
Schalkamp et al. 2023 Nat Med: UK Biobank wearable accelerometry (n=103,712) — gait patterns predicted PD diagnosis 7 years before clinical diagnosis using machine learning.[31]
8.4 Biological Staging — SynBioS / SynNDex Framework
Simuni et al. 2024 Lancet Neurol PMID 38267190 — proposed redefinition of PD biologically:[24]
- α-syn SAA positivity = "Neuronal α-synuclein disease" — regardless of clinical stage (parallel to AD ATN framework)
- Staging: S (SAA) → N (nigrostriatal/dopaminergic) → D (clinical disease)
- Stage 0: SAA+ only, no dopaminergic or clinical markers; Stage 1: SAA+ + dopaminergic; Stage 2: full motor clinical syndrome
Hatano et al. 2026 J Neurochem PMID 42261981: updates the biological framework integrating α-syn, DAT, and fluid biomarkers — moving toward a unified staging system across the PD spectrum.[43]
- iRBD 是最強前驅標記（LR+ ~130）；14 年累積轉化率 ~85–90%；α-syn SAA 陽性率 >80%
- Body-first（腸道→腦）vs Brain-first（腦→周邊）：不同前驅表現、可能影響未來治療策略
- SAA 動力學參數（lag phase）可預測前驅期患者轉化速度，有助於保護性試驗分層
- 穿戴式裝置加速度計：發病前 7 年已可偵測步態異常 —— 未來大規模篩查工具
- SynBioS 生物分期（S+N+D）類比 AD ATN 框架；LRRK2-PD SAA 陰性率 ~32% 是主要挑戰
Take-Home Messages
- Bradykinesia with amplitude decrement is mandatory — rest tremor and rigidity are additional features; absence of tremor does NOT exclude PD (PIGD phenotype).
- MDS 2015 criteria: Probable PD yields sensitivity ~96%, specificity ~95% — always actively screen for absolute exclusion criteria and red flags; "no levodopa response" exclusion requires adequate dose at moderate severity.
- DAT-SPECT distinguishes neurodegenerative from non-degenerative parkinsonism (ET, DIP) — it cannot separate PD from PSP/MSA/CBS; normal DAT = absolute exclusion criterion for PD.
- α-Syn SAA (CSF ~91%, skin ~93% sensitivity) is the most transformative advance since DAT-SPECT — enabling biological confirmation of synucleinopathy and prodromal detection years before motor onset; LRRK2-PD may be SAA-negative (~32%).
- iRBD patients have ~85–90% 14-year phenoconversion risk and >80% SAA positivity — they deserve SAA testing, DAT-SPECT, and proactive enrolment in neuroprotection trials.
References
48 papers · all PMIDs verified · 2026-06-19 (updated: +3 local Drive sources)- Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591–1601. PMID 26474316 [Classic reference]
- Postuma RB, Poewe W, Litvan I, et al. Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2018;33(10):1601–1608. PMID 30145797
- Hess CW, Hallett M. The Phenomenology of Parkinson's Disease. Semin Neurol. 2017;37(2):109–119. PMID 28511251
- Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284–2303. PMID 33848468
- Goetz CG, Tilley BC, Shaftman SR, et al. MDS-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170. PMID 19025984 [Classic reference]
- Wagle Shukla A. Diagnosis and Treatment of Essential Tremor. Continuum (Minneap Minn). 2022;28(5):1333–1358. PMID 36222768
- Conn H, Jankovic J. Drug-induced parkinsonism: diagnosis and treatment. Expert Opin Drug Saf. 2024;23(12):1505–1516. PMID 39419777
- Fox SH, Luca DG, Postuma RB, et al. Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases. NPJ Parkinsons Dis. 2025;11(1):360. PMID 41390531
- Horváth K, Aschermann Z, Ács P, et al. Minimal clinically important difference on the Motor Examination part of MDS-UPDRS. Parkinsonism Relat Disord. 2015;21(12):1421–1426. PMID 26578041
- Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323(6):548–560. PMID 32044947
- Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. Lancet Neurol. 2021;20(5):385–397. PMID 33894193
- Morbelli S, Esposito G, Arbizu J, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging. 2020;47(7):1885–1912. PMID 32388612
- Kawazoe M, Arima H, Maeda T, et al. Sensitivity and specificity of cardiac ¹²³I-MIBG scintigraphy for diagnosis of early-phase Parkinson's disease. J Neurol Sci. 2019;407:116438. PMID 31706063
- Siderowf A, Concha-Marambio L, Lafontant DE, et al. Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407–417. PMID 37059509
- Gibbons CH, Levine T, Adler C, et al. Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies (SYNABS study). JAMA. 2024;331(15):1298–1306. PMID 38506839
- Gibbons C, Wang N, Rajan S, et al. Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease. Neurology. 2023;100(15):e1529–e1539. PMID 36657992
- Wang Z, Becker K, Donadio V, et al. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol. 2021;78(1):30–40. PMID 32986090
- Zheng Y, Li S, Yang C, et al. Comparison of biospecimens for α-synuclein seed amplification assays in Parkinson's disease: A systematic review and network meta-analysis. Eur J Neurol. 2023;30(12):3949–3967. PMID 37573472
- Iranzo A, Mammana A, Muñoz-Lopetegi A, et al. Misfolded α-Synuclein Assessment in the Skin and CSF by RT-QuIC in Isolated REM Sleep Behavior Disorder. Neurology. 2023;100(18):e1898–e1910. PMID 36931726
- Agin-Liebes J, Lodge A, Reddy H, et al. α-synuclein biomarker assays: bridging research and patient care. Lancet Neurol. 2025;24(8):681–697. PMID 40683277
- Orrú CD, Vaughan DP, Vijiaratnam N, et al. Diagnostic and prognostic value of α-synuclein seed amplification assay kinetic measures in Parkinson's disease: a longitudinal cohort study. Lancet Neurol. 2025;24(7):580–590. PMID 40541208
- Ma Y, Farris CM, Weber S, et al. Sensitivity and specificity of a seed amplification assay for diagnosis of multiple system atrophy: a multicentre cohort study. Lancet Neurol. 2024;23(12):1248–1258. PMID 39577923
- Anastassiadis C, Martinez-Valbuena I, Vasilevskaya A, et al. CSF α-Synuclein Seed Amplification Assay in Patients With Atypical Parkinsonian Disorders. Neurology. 2024;103(8):e209818. PMID 39208367
- Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024;23(2):178–190. PMID 38267190
- Okubadejo NU, Okun MS, Jankovic J. Tapping the Brakes on New Parkinson Disease Biological Staging. JAMA Neurol. 2024;81(8):793–795. PMID 38976240
- Heinzel S, Berg D, Gasser T, et al. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2019;34(10):1464–1470. PMID 31412427
- Berg D, Borghammer P, Fereshtehnejad SM, et al. Prodromal Parkinson disease subtypes — key to understanding heterogeneity. Nat Rev Neurol. 2021;17(6):349–361. PMID 33879872
- Borghammer P, Van Den Berge N. Brain-First versus Gut-First Parkinson's Disease: A Hypothesis. J Parkinsons Dis. 2019;9(Suppl 2):S281–S295. PMID 31498132
- Joza S, Hu MT, Jung KY, et al. Progression of clinical markers in prodromal Parkinson's disease and dementia with Lewy bodies: a multicentre study. Brain. 2023;146(8):3258–3272. PMID 36881989
- Coughlin DG, Shifflett B, Farris CM, et al. α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson Disease. Neurology. 2025;104(5):e210279. PMID 39913882
- Schalkamp AK, Peall KJ, Harrison NA, Daffertshofer A. Wearable movement-tracking data identify Parkinson's disease years before clinical diagnosis. Nat Med. 2023;29(8):2048–2056. PMID 37400639
- Vaillancourt DE, Barmpoutis A, Wu SS, et al. Automated Imaging Differentiation for Parkinsonism (AID-P trial). JAMA Neurol. 2025;82(5):446–455. PMID 40094699
- Haller S, He N, Schwarz S, et al. Clinical MRI Biomarkers to Differentiate Parkinson Disease from Its Mimics. Radiology. 2025;317(3):e242044. PMID 41085393
- Martinez-Valbuena I, Emamikhah M, Olszewska DA, et al. A multimodal biomarker strategy to enhance diagnostic precision in neurodegenerative parkinsonism. Nat Med. 2026;32(6):1–12. PMID 42157002
- Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021;7(1):47. PMID 34210995
- Cong S, Xiang C, Zhang S, et al. Prevalence and clinical aspects of depression in Parkinson's disease: A systematic review and meta-analysis of 129 studies. Neurosci Biobehav Rev. 2022;141:104749. PMID 35750224
- Pagonabarraga J, Bejr-Kasem H, Martinez-Horta S, Kulisevsky J. Parkinson disease psychosis: from phenomenology to neurobiological mechanisms. Nat Rev Neurol. 2024;20(3):142–156. PMID 38225264
- Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease — an evidence-based medicine review. Mov Disord. 2019;34(2):180–198. PMID 30653247
- Keir G, Roytman M, Mashriqi F, et al. Atypical Parkinsonian Syndromes: Structural, Functional, and Molecular Imaging Features. AJNR Am J Neuroradiol. 2024;45(12):1811–1823. PMID 39209485
- McGregor MM, Nelson AB. Circuit Mechanisms of Parkinson's Disease. Neuron. 2019;101(6):1042–1056. PMID 30897356
- Rawls A, Okun MS. Parkinson Disease. Continuum (Minneap Minn). 2025;31(4):1073–1109. PMID 40748114
- Zarkali A, Thomas GEC, Zetterberg H, Weil RS. Neuroimaging and fluid biomarkers in Parkinson's disease in an era of targeted interventions. Nat Commun. 2024;15(1):5661. PMID 38969680
- Hatano T, Lin CH, Cardoso F. A Biological Framework for Parkinson's Disease: Advances in α-Synuclein-Centered Biomarkers and Staging. J Neurochem. 2026;170(6):e70491. PMID 42261981
- Liu M, Wen T, Luo H, et al. Distinct cutaneous α-synuclein signatures in body-first and brain-first Parkinson's disease subtypes. Brain. 2026;149(5):awaf395. PMID 41105632
- Munhoz RP, Tumas V, Pedroso JL, et al. The clinical diagnosis of Parkinson's disease. Arq Neuropsiquiatr. 2024;82(6):1–14. PMID 38325391
- Morris HR, Lees AJ. Limitations of the α-Synuclein Seed Amplification Assay in Clinical Practice: Understanding the Pathological Diversity of Parkinson Syndrome. JAMA Neurol. 2024;81(9):916–918. PMID 39102226 Local Drive ↗
- Jagusch F, Redl E, Theyer C, et al. Cardiac MIBG Scintigraphy in Neurodegenerative Parkinsonism: Limitations in Clinical Practice. Mov Disord Clin Pract. 2026. PMID 42037015 Local Drive ↗
- Thaler A, Alcalay RN. Diagnosis and Medical Management of Parkinson Disease. Continuum (Minneap Minn). 2022;28(5):1281–1310. PMID 36222765 Local Drive ↗